1-2 of 2
Jay Yang
Close
Sort by
Journal Articles

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1 -mutated AML

Clinical Trials & Observations
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3117–3127.
https://doi.org/10.1182/bloodadvances.2022009411
Published: 2023
Includes: Supplemental data
Journal Articles

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Clinical Trials & Observations
Talha Badar, Aniko Szabo, Anjali Advani, Martha Wadleigh, Shukaib Arslan, Muhammad Ali Khan, Ibrahim Aldoss, Caitlin Siebenaller, Elizabeth Schultz, Mehrdad Hefazi, Rory M. Shallis, Ilana Yurkiewicz, Nikolai Podoltsev, Anand A. Patel, Emily Curran, Suresh Balasubramanian, Jay Yang, Ryan J. Mattison, Madelyn Burkart, Shira Dinner, Michaela Liedtke, Mark R. Litzow, Ehab Atallah
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2308–2316.
https://doi.org/10.1182/bloodadvances.2019001381
Published: 2020
Includes: Supplemental data